704 related articles for article (PubMed ID: 26791002)
1. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Atanackovic D; Radhakrishnan SV; Bhardwaj N; Luetkens T
Br J Haematol; 2016 Mar; 172(5):685-98. PubMed ID: 26791002
[TBL] [Abstract][Full Text] [Related]
2. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T-cell therapies for multiple myeloma.
Mikkilineni L; Kochenderfer JN
Blood; 2017 Dec; 130(24):2594-2602. PubMed ID: 28928126
[TBL] [Abstract][Full Text] [Related]
4. CARs in the Lead Against Multiple Myeloma.
Ormhøj M; Bedoya F; Frigault MJ; Maus MV
Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
6. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
7. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T cell therapies for multiple myeloma.
Wu C; Zhang L; Brockman QR; Zhan F; Chen L
J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
[TBL] [Abstract][Full Text] [Related]
9. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
11. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
12. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
Feinberg D; Paul B; Kang Y
Cell Immunol; 2019 Nov; 345():103964. PubMed ID: 31492448
[TBL] [Abstract][Full Text] [Related]
13. The activated conformation of integrin β
Hosen N; Matsunaga Y; Hasegawa K; Matsuno H; Nakamura Y; Makita M; Watanabe K; Yoshida M; Satoh K; Morimoto S; Fujiki F; Nakajima H; Nakata J; Nishida S; Tsuboi A; Oka Y; Manabe M; Ichihara H; Aoyama Y; Mugitani A; Nakao T; Hino M; Uchibori R; Ozawa K; Baba Y; Terakura S; Wada N; Morii E; Nishimura J; Takeda K; Oji Y; Sugiyama H; Takagi J; Kumanogoh A
Nat Med; 2017 Dec; 23(12):1436-1443. PubMed ID: 29106400
[TBL] [Abstract][Full Text] [Related]
14. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
15. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
Stauss HJ; Morris EC
Gene Ther; 2013 Nov; 20(11):1029-32. PubMed ID: 23804078
[TBL] [Abstract][Full Text] [Related]
19. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
Frey NV; Porter DL
Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
Front Immunol; 2019; 10():1613. PubMed ID: 31379824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]